FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading

  • Gabriele PöpperlEmail author
  • Friedrich W. Kreth
  • Jan H. Mehrkens
  • Jochen Herms
  • Klaus Seelos
  • Walter Koch
  • Franz J. Gildehaus
  • Hans A. Kretzschmar
  • Jörg C. Tonn
  • Klaus Tatsch
Original article



Treatment and prognosis of gliomas depend on their histological tumour grade. The aim of the study was to evaluate the potential of [18F]fluoroethyltyrosine (FET) PET for non-invasive tumour grading in untreated patients.


Dynamic FET PET studies were performed in 54 patients who, based on MRI, were estimated to have low grade (LG; n = 20), intermediate (WHO II–III; n = 4) or high grade (HG; n = 30) tumours. For standard evaluation, tumour SUVmax and the ratio to background (SUVmax/BG) were calculated (sum image: 20–40 min). For dynamic evaluation, mean SUV values within a 90% isocontour ROI (SUV90) and the SUV90/BG ratios were determined for each time frame to evaluate the course of FET uptake. Results were correlated with histopathological findings from PET-guided stereotactic biopsies.


Histology revealed gliomas in all patients. Using the standard method a statistically significant difference (p = 0.001) was found between LG (n = 20; SUVmax/BG: 2.16 ± 0.98) and HG (n = 34; SUVmax/BG: 3.29 ± 1.06) gliomas (opt. threshold 2.58: SN71%/SP85%/area under ROC curve [AUC]:0.798), however, with a marked overlap between WHO II to IV tumours. Time activity curves showed slight increase in LG, whereas HG tumours presented with an early peak (10–20 min) followed by a decrease. Dynamic evaluation successfully separated LG from HG gliomas with higher diagnostic accuracy (SN94%/SP100%/AUC:0.967).


Based on the ratio-based method, a statistically significant difference was found between LG and HG gliomas. Due to the interindividual variability, however, no reliable individual grading was possible. In contrast, dynamic evaluation allowed LG and HG gliomas to be differentiated with high diagnostic power and, thus, should supplement the conventional method.


Untreated gliomas Grading Dynamic FET PET Stereotactic biopsy 



Part of this work was supported by grant 10-3163-Wi3 from Deutsche Krebshilfe.


  1. 1.
    Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479–89.PubMedGoogle Scholar
  2. 2.
    Kleihues P, Cavenee WK. Tumors of the nervous system. Pathology and genetics. Lyon, France: IARC Press; 2000.Google Scholar
  3. 3.
    Earnest Ft, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823–7.PubMedGoogle Scholar
  4. 4.
    Pierallini A, Bonamini M, Bozzao A, Pantano P, Stefano DD, Ferone E, et al. Supratentorial diffuse astrocytic tumours: proposal of an MRI classification. Eur Radiol 1997;7:359–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Asari S, Makabe T, Katayama S, Itoh T, Tsuchida S, Ohmoto T. Assessment of the pathological grade of astrocytic gliomas using an MRI score. Neuroradiology 1994;36:308–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Glantz MJ, Burger PC, Herndon JE 2nd, Friedman AH, Cairncross JG, Vick NA, et al. Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 1991;41:1741–4.PubMedGoogle Scholar
  7. 7.
    Borbely K, Nyary I, Toth M, Ericson K, Gulyas B. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006;246:85–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 2004;101:476–83.PubMedGoogle Scholar
  10. 10.
    Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Rachinger W, Goetz C, Popperl G, Gildehaus FJ, Kreth FW, Holtmannspotter M, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57:505–11, discussion 505–511.PubMedCrossRefGoogle Scholar
  13. 13.
    Popperl G, Gotz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, et al. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006;33:792–800.PubMedCrossRefGoogle Scholar
  14. 14.
    Popperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspotter M, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005;32:1018–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S. Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med 2005;19:677–83.PubMedGoogle Scholar
  16. 16.
    Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[(11)C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, et al. [11C]L-methionine uptake in gliomas. Neurosurgery 1989;25:720–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Popperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47:393–403.PubMedGoogle Scholar
  19. 19.
    Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K, et al. O-(2-[(18)F]fluorethyl)-L: -tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Kreth FW, Muacevic A, Medele R, Bise K, Meyer T, Reulen HJ. The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours-a prospective study. Acta Neurochir (Wien) 2001;143:539–45, discussion 545–546.CrossRefGoogle Scholar
  21. 21.
    Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. Invest Radiol 1979;14:109–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36.PubMedGoogle Scholar
  23. 23.
    Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85.PubMedGoogle Scholar
  24. 24.
    De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006;27:1432–7.PubMedGoogle Scholar
  26. 26.
    Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Stober B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 2006;33:932–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Lahoutte T, Caveliers V, Camargo SM, Franca R, Ramadan T, Veljkovic E, et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 2004;45:1591–6.PubMedGoogle Scholar
  29. 29.
    Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999;45:1279–91, discussion 191.PubMedCrossRefGoogle Scholar
  30. 30.
    Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45–53.PubMedGoogle Scholar
  31. 31.
    Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360–71.PubMedCrossRefGoogle Scholar
  32. 32.
    Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47–52.PubMedGoogle Scholar
  33. 33.
    Gupta K, Radotra BD, Banerjee AK, Nijhawan R. Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors. Anal Quant Cytol Histol 2004;26:223–9.PubMedGoogle Scholar
  34. 34.
    Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, et al. “Facilitated” amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998;18:500–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Langen KJ, Jarosch M, Muhlensiepen H, Hamacher K, Broer S, Jansen P, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 2003;30:501–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999;40:1367–73.PubMedGoogle Scholar
  37. 37.
    Meier C, Ristic Z, Klauser S, Verrey F. Activation of system L heterodimeric amino acid exchangers by intracellular substrates. Embo J 2002;21:580–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990;70:43–77.PubMedGoogle Scholar
  39. 39.
    Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999;40:205–12.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Gabriele Pöpperl
    • 1
    Email author
  • Friedrich W. Kreth
    • 2
  • Jan H. Mehrkens
    • 2
  • Jochen Herms
    • 3
  • Klaus Seelos
    • 4
  • Walter Koch
    • 1
  • Franz J. Gildehaus
    • 1
  • Hans A. Kretzschmar
    • 3
  • Jörg C. Tonn
    • 2
  • Klaus Tatsch
    • 1
  1. 1.Department of Nuclear Medicine, Klinikum GroßhadernUniversity of MunichMunichGermany
  2. 2.Department of Neurosurgery, Klinikum GroßhadernUniversity of MunichMunichGermany
  3. 3.Institute for NeuropathologyUniversity of MunichMunichGermany
  4. 4.Department of Neuroradiology, Klinikum GroßhadernUniversity of MunichMunichGermany

Personalised recommendations